Cancer chemotherapy and pharmacology
-
Cancer Chemother. Pharmacol. · Jul 2002
Randomized Controlled Trial Comparative Study Clinical TrialUrinary and fecal excretion of topotecan in patients with malignant solid tumours.
The objectives of the study were to determine the pharmacokinetics and routes of excretion of topotecan following intravenous or oral administration to patients with refractory solid tumours. ⋯ Fecal and urinary excretion of unchanged topotecan were the major routes of topotecan elimination. Approximately 28% of the intravenous dose and 43% of the oral dose of topotecan were unaccounted for and eliminated through other routes.
-
Cancer Chemother. Pharmacol. · Jul 2002
Multicenter StudyA population analysis of the pharmacokinetics of Cremophor EL using nonlinear mixed-effect modelling.
The purpose of this study was to develop a population pharmacokinetic model for Cremophor EL used as a formulation vehicle for paclitaxel. ⋯ The population model was able to adequately describe the pharmacokinetic parameters and influence of covariates on the pharmacokinetics of Cremophor EL. This model can be used when studying the relationship between the pharmacokinetics and toxicity of Cremophor EL, and the drug's influence on the pharmacokinetics of paclitaxel.